Form 4: Acrivon Therapeutics CFO Rasmus Holm-Jorgensen Reports Stock Option Grant

Rasmus Holm-Jorgensen, CFO of Acrivon Therapeutics, reports the acquisition of stock options on March 1, 2025.

Summary

• On March 1, 2025, Rasmus Holm-Jorgensen, the Chief Financial Officer of Acrivon Therapeutics, Inc., was granted stock options to purchase 109,309 shares of common stock.
• The exercise price of the stock options is $5.31 per share.
• 25% of the shares will vest on March 1, 2026, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Future Outlook

The vesting schedule suggests a long-term commitment from the CFO to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
• The CFO is incentivized to contribute to the company's growth and profitability.

Key Dates